Imaging of HER-2 Overexpression in Tumors for Guiding Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|14|28|2999-3019

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.28, 2008-10, pp. : 2999-3019

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities

By  

Current Pharmaceutical Design, Vol. 14, Iss. 28, 2008-10 ,pp. : 2983-2998

Bentham Science Publishers

Access to resources Recommend Favorite

The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors

By  

Current Cancer Drug Targets, Vol. 5, Iss. 2, 2005-03 ,pp. : 139-148

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-HER2 Cancer Therapy and Cardiotoxicity

By  

Current Pharmaceutical Design, Vol. 20, Iss. 30, 2014-09 ,pp. : 4911-4919

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacodiagnostic Testing in Breast Cancer: Focus on HER2 and Trastuzumab Therapy

By Bartlett John M.S.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 5, 2005-01 ,pp. : 303-315

Adis International

Access to resources Recommend Favorite

Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 148-162

Bentham Science Publishers

Access to resources Recommend Favorite